A personalized mRNA cancer vaccine combined with the immunotherapy drug Keytruda cut the risk of melanoma recurrence or death by 49% over five years, according to long-term follow-up data presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The results extend earlier findings and offer one of the most compelling signals yet that custom-built mRNA vaccines could become a cornerstone of cancer treatment.
The trial pairs Moderna’s experimental vaccine, known as intismeran autogene (mRNA-4157/V940), with Merck’s checkpoint inhibitor pembrolizumab (Keytruda). The combination is being evaluated in patients who had already undergone surgery for high-risk stage III or IV melanoma — patients who, despite surgery, face a steep chance of the cancer returning.
What the 5-Year Data Show
The findings come from KEYNOTE-942/mRNA-4157-P201, a Phase 2b trial that enrolled 157 patients between 2019 and 2021. Participants were randomized to receive either Keytruda alone — the current standard of care after surgery for high-risk melanoma — or Keytruda combined with the personalized mRNA vaccine.
At five years of follow-up, researchers reported several striking results:
- 49% reduction in the risk of recurrence or death in the combination group compared with Keytruda alone.
- 59% reduction in the risk of distant metastasis (cancer spreading to organs such as the lungs, liver, or brain).
- Five-year overall survival of 92.2% in the combination arm, versus 71.3% for patients receiving Keytruda alone.
“What we are seeing now at five years is a durable benefit,” said Dr. Matteo Carlino of Melanoma Institute Australia, who presented the data. Senior investigator Dr. Janice Mehnert of NYU Grossman School of Medicine noted that the magnitude and persistence of the effect “supports the potential for personalized neoantigen therapy to change how we treat melanoma.”
How a Personalized mRNA Cancer Vaccine Works
Unlike infectious-disease vaccines that target a shared pathogen, this therapy is custom-built for each patient. Researchers sequence the tumor removed during surgery, identify mutations unique to that cancer, and then design an mRNA vaccine encoding up to 34 of those mutated proteins, known as neoantigens.
Once injected, the mRNA instructs cells to produce these tumor-specific proteins, training the immune system to recognize and attack any cancer cells that carry them. Keytruda complements that response by blocking the PD-1 checkpoint, a “brake” tumors exploit to evade immune attack. According to the National Cancer Institute, checkpoint inhibitors like pembrolizumab have already transformed outcomes in advanced melanoma over the past decade.
The combination, in theory, gives the immune system both a clearer target and a louder signal to act — a one-two punch researchers had long hoped for.
Safety: A Surprising Bonus
A key concern with cancer immunotherapy is immune-related adverse events, such as colitis, thyroid dysfunction, and skin inflammation. Combining two immune-activating therapies often raises these risks. Yet in this trial, adding the vaccine to Keytruda did not increase the rate of immune-related side effects, and was actually associated with a slightly lower rate, the investigators reported.
That is a notable contrast to prior strategies that paired Keytruda with a second checkpoint inhibitor, which tend to boost efficacy at the cost of more toxicity.
Why It Matters for the Future of Cancer Care
Melanoma is one of the most aggressive skin cancers. The American Cancer Society estimates that more than 100,000 new invasive cases are diagnosed each year in the United States, and high-risk stage III disease carries a substantial recurrence rate even after surgery. Tools that extend disease-free survival in this group can translate into years of healthy life.
The 5-year results matter for three reasons:
- Durability. Early benefits often fade. A sustained 49% reduction at five years suggests the immune memory created by the vaccine is long-lasting.
- Platform validation. If mRNA technology can be programmed against melanoma, the same approach is now being tested in lung, kidney, bladder, and head-and-neck cancers.
- Manufacturing feasibility. The trial showed personalized vaccines can be produced within weeks of surgery — a logistic hurdle that had to be solved before any wider rollout.
A larger Phase 3 confirmatory trial, INTerpath-001, is now enrolling patients globally. Regulators in the United States and Europe will weigh that data before deciding whether the combination becomes a standard option.
What This Doesn’t Mean Yet
Several caveats are worth keeping in mind. The 157-patient trial was relatively small, and overall survival differences in early-phase studies can shift in larger populations. The vaccine is also not yet approved by the U.S. Food and Drug Administration; it remains investigational. And it is designed for patients with high-risk melanoma after surgery — not for prevention, and not, at this stage, for cancers other than melanoma.
“This is a meaningful step, not the finish line,” Dr. Mehnert cautioned. Research suggests broader adoption will depend on Phase 3 confirmation, real-world durability, and access to the genomic sequencing infrastructure these vaccines require.
Steps People Can Take Today
While personalized cancer vaccines are still in trials, the best evidence-backed ways to lower melanoma risk remain unchanged. The Centers for Disease Control and Prevention recommend:
- Limiting UV exposure, especially between 10 a.m. and 4 p.m.
- Using broad-spectrum sunscreen with SPF 30 or higher.
- Avoiding tanning beds.
- Checking the skin regularly for new or changing moles and discussing any concerns with a healthcare provider.
For people already diagnosed with melanoma, clinical trial participation is one way to access emerging therapies. The National Cancer Institute maintains a searchable trial database, and oncology teams can advise on eligibility.
The Bottom Line
Five-year data from KEYNOTE-942 mark the most mature evidence yet that an mRNA cancer vaccine, paired with an established immunotherapy, can produce a durable benefit in high-risk melanoma. If Phase 3 results confirm the signal, personalized neoantigen vaccines may shift from experimental science to a routine part of how aggressive cancers are managed after surgery.
Disclosure: This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before making changes to your health regimen.